Blog

Yüksel Ürün: The impact of comorbidities on survival in cancer patients receiving ICIs

Yüksel Ürün/X

Jan 29, 2025, 22:14

Yüksel Ürün: The impact of comorbidities on survival in cancer patients receiving ICIs

Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine in Turkey, shared a post on X about recent paper by Merih Yalçıner et al., titled “Impact of comorbidities on survival in cancer patients receiving immune checkpoint inhibitors” published on Springer Nature Link.

Authors: Merih Yalçıner, Satı Coşkun Yazgan, Eda Eylemer Mocan, Beliz Bahar Karaoğlan, Hatice Bölek, Emre Yekedüz, Yüksel Ürün

“Exciting News!

Proud to share our latest research on the impact of comorbidities on survival in cancer patients receiving immune checkpoint inhibitors! Great teamwork pays off!”

Beliz Bahar Karaoğlan cancer Eda Eylemer Mocan Emre Yekedüz Hatice Bölek Immune Checkpoint Inhibitors Merih Yalçıner OncoDaily Oncology Satı Coskun Yazgan Yüksel Ürün

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25